Arena Pharmaceuticals, Inc.
6166 Nancy Ridge Drive
440 articles with Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals Highlights Strategic Plan Driving Near and Long-term Growth with Eight Ph 2 and Ph 3 Data Readouts in 2020-21 and One New IND Per Year for the Next 5 Years
Arena Pharmaceuticals, Inc. will provide a corporate update highlighting its strategic portfolio expansion on a conference call tomorrow, January 7, at 9:00 AM ET, and provide additional detail at the 38th Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2020.
10/28/2019Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look.
7/29/2019A number of companies reported clinical trial data last week. Here’s a look.
Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
Arena Pharmaceuticals, Inc. announced that the first subject has been dosed in ELEVATE UC 52, the first of two pivotal trials within the Phase 3 ELEVATE UC registrational program evaluating etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis.
Arena Pharmaceuticals, Inc. announced that members of its senior management team will participate at the upcoming investor conferences
Arena Pharmaceuticals, Inc. announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 12:00 PM EDT.
For anyone who has ever visited San Diego, there is an automatic appeal of the city’s laid-back vibe and incredibly pleasant temperatures.
Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation
Arena Pharmaceuticals, Inc. presented new Phase 2 data from its investigative drug candidates etrasimod and olorinab at the 14th Congress of European Crohn's and Colitis Organisation.
Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
Etrasimod demonstrated clinical response and durable, long-term clinical remission and favorable long-term safety and tolerability in an open-label extension trial
Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27
Arena Pharmaceuticals, Inc. announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 9:30 AM EST.
Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress
Arena Pharmaceuticals, Inc. will present preclinical and early clinical development data from its investigative drug candidate olorinab at the Crohn's & Colitis Congress® in Las Vegas, NV.
United Therapeutics Corporation announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA).
Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag
Arena Pharmaceuticals, Inc. announced the closing of the global license agreement with United Therapeutics Corporation for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
12/3/2018Biotechs and pharmas strengthened their leadership teams with these appointments. Find news from Mersana, Foamix, Allergan, and more.
Arena Pharmaceuticals Presented Preclinical Data for APD418 in Development for Treatment of Decompensated Heart Failure at American Heart Association Scientific Sessions
Arena Pharmaceuticals, Inc presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), ß3 adrenergic receptor (AdrR) selective antagonist, at the American Heart Association Scientific Sessions 2018.
Arena Pharmaceuticals Appoints Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors
Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA), a biopharmaceutical company focused on delivering novel, transformational medicines across multiple therapeutic areas, today announced the appointment of Kieran T. Gallahue as a non-executive director. Mr. Gallahue is a highly accomplished executive with over 25 years of leadership experience in publicly-traded life sciences companies.
"We are pleased with the progress we achieved during the third quarter, hitting multiple milestones for our lead programs," said Amit D. Munshi, President and CEO of Arena.
Arena to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7
Arena, today announced that the Company will release its third quarter 2017 financial results and provide a corporate update on Tuesday, November 7, 2017, after the close of the U.S. financial markets.
Arena To Present Additional Pre-Clinical Data On Ralinepag For Treatment Of Pulmonary Arterial Hypertension At European Society Of Cardiology Congress